Lower riskDrug recall · FDA · Published May 4, 2021
Boehringer Ingelheim Micardis Tablets 80mg Recall: Subpotent Drug Risk
Boehringer Ingelheim recalls 80mg Micardis tablets (NDC 0597-0041-37) due to subpotent drug content. Patients may not get full treatment effect. Contact for return instructions.
“Boehringer Ingelheim Micardis Tablets 80mg Recall: Subpotent Drug Risk.” GovInfoNow, updated October 4, 2026. https://govinfonow.com/recall/36155-boehringer-ingelheim-micardis-tablets-80mg-recall-subpotent-drug-risk. Based on FDA recall #D-0600-2021 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0600-2021%22&limit=1).
Boehringer Ingelheim Pharmaceuticals, Inc. recalled Micardis Tablets (telmisartan) 80 mg, 30 ct., distributed by the company, due to subpotent drug risks, according to the FDA on May 4, 2021.
The recall addresses subpotent drug risks associated with the affected Micardis Tablets. The FDA classified this as a Class II recall.
Context
GovInfoNow's records show Boehringer Ingelheim Pharmaceuticals, Inc. has had 9 other recalls on record since Oct. 6, 2016. Other recent recalls of similar products include Synjardy XR Tablets Recall (June 12, 2026), JARDIANCE 25mg Tablets Label Mix-Up Recall (March 9, 2023), and Boehringer Ingelheim Recalls Catapres 0.1 mg Tablets Due to Testing Issue (Oct. 5, 2020). Other recent recalls of similar products include Ascend Laboratories recalls Amlodipine/Olmesartan tablets with low drug content (July 8, 2026), Unichem busPIRone 5mg Tablets Recall: Subpotent Drug Risk (April 13, 2026), and Major Pharmaceuticals Levothyroxine Tablets Recall: Subpotent Drug Risk (July 13, 2026).
How to tell if you have this one
Check for Micardis Tablets (80mg, 30-count) with NDC 0597-0041-37 and lot number 860412 from September 2022. These are prescription-only products.
Brand
Boehringer Ingelheim
Category
Drug
Based on the official FDA remedy
What to do — step by step
Check Medication Details
Verify your Micardis tablets have NDC 0597-0041-37 and lot number 860412 from September 2022.
Where it went and when
Where it was distributed
Distributed in 10 states and Puerto Rico.
Listed by the agency
Not listed
FDA distribution: “AR, CO, CT, LA, NC, ND, NH, NJ, OH, PA and PR” States read from FDA’s own wording; “not listed” means the notice does not name it.
States: Arkansas, Colorado, Connecticut, Louisiana, New Hampshire, New Jersey, North Carolina, North Dakota, Ohio, Pennsylvania, Puerto Rico.
Recall timeline
FDA terminated this recall 5 months after the firm started it.
1Firm started the recall
2FDA classified it Class II
3Published in FDA’s Enforcement Report
4FDA terminated the recall
Dates from the agency record only; steps without a date are left out.
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
Official source: FDA Recall #D-0600-2021 (May 4, 2021) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0600-2021 to see it in context.
Plain-language summary written by qwen3:4b on October 4, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.